3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
28
Small Cell Lung Carcinoma
24
Fallopian Tube Neoplasms
12
Uterine Cervical Neoplasms
8
Carcinoma, Ovarian Epithelial
8
Neuroblastoma
7
Lung Neoplasms
6
Sarcoma
3
Neoplasms
3
Retinoblastoma
2
Neoplasm Metastasis
2
Malignant mesenchymal tumor
2
Ganglioneuroblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Solid Tumors
1
SCLC
1
Rhabdomyosarcoma
1
Retinal Neoplasms
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Localized Extraskeletal Ewing Sarcoma
1
Leukemia
1
Eye Neoplasms
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Carcinoma
1
Interventions
Carboplatin
8
Paclitaxel
7
Hyperthermic Intraperitoneal Chemotherapy
7
Bevacizumab
4
liposomal doxorubicin
3
Gemcitabine
3
Oxaliplatin
2
Neoadjuvant Therapy
2
relacorilant
1
phenoxodiol
1
pembrolizumab
1
oregovomab
1
olaparib
1
nintedanib
1
lobaplatin
1
lanreotide
1
epothilone B
1
atezolizumab
1
Trabectedin
1
Topotecan
1
Therapeutics
1
Surgical Procedures, Operative
1
Saline Solution
1
Leucovorin
1
Letrozole
1
Laparotomy
1
Laparoscopy
1
LAIF 900
1
Hypericum extract LI 160
1
Glucose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Peritoneal Neoplasms
×
Topotecan
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled